March 30 (Bloomberg) -- Heart stents made by BostonScientific Corp., the world’s biggest seller of the artery-clearing devices, were less effective in studies than those fromAbbott Laboratories, Johnson & Johnson and Medtronic Inc. Taxus Liberte, Boston Scientific’s newest stent, requiredmore repeat ...Read More
The U.S. Department of Justice filed charges against Boston Scientific Corp.'s Guidant division Thursday, saying Guidant did not fully disclose problems with its devices to regulators. The charges are part of a previously announced agreement for Boston Scientific Corp. to plead ...Read More
The U.S. Justice Department Thursday charged Guidant Corp. with criminal violations of federal laws related to safety problems and the subsequent recall of heart defibrillators in 2005. The charges were expected for Arden Hills-based Guidant, now part of Boston Scientific Corp. ...Read More
(Adds sales figures in seventh paragraph.) Feb. 23 (Bloomberg) -- Medtronic Inc., the biggest maker of heart-rhythm devices, said third-quarter profit rose 19 percent on increased sales of its defibrillators and pacemakers and raised the lower end of its 2010 earnings ...Read More
FDA eyes overhaul for medical device approvals WASHINGTON — Manufacturers of pacemakers, drug pumps and other implants could be the latest industry due for a safety overhaul, as the Food and Drug Administration takes a second look at how many devices ...Read More
Analysts and investors were harsh critics of Boston Scientific Thursday after the company's latest restructuring announcement failed to inspire much confidence. The medical devices company reported a fourth-quarter loss of $1.1 billion, or 71 cents per share, compared with a loss ...Read More
Boston Scientific Corp. (BSX) indicated Thursday that the road to improvement remains long. The company's soft financial forecasts and fresh restructuring plans shows it's going to take time and patience from investors to overcome challenges that include slow growth, sliding product ...Read More
Shares of Boston Scientific tumbled Thursday as analysts and investors showed their lack of confidence in the company's ability to make a quick turnaround. The medical devices company reported a fourth-quarter loss of $1.1 billion, or 71 cents per share, compared ...Read More
Google Inc.: Standard & Poor's equity analyst Scott Kessler reiterated his buy rating on shares of Google Inc. (GOOG) on Feb. 11. On Feb. 10, Google, owner of the world's most popular Web-search engine, said it is planning to build high-speed ...Read More
Boston Scientific, the world's second-largest maker of heart devices, reported its fourth-quarter loss narrowed on higher sales of cardiac rhythm devices. The Natick, Mass.-based company's loss was $1.08 billion, or 71 cents a share, compared to a loss of $2.39 billion ...Read More
Boston Scientific Corp. (BSX) announced on Wednesday sweeping restructuring moves that include eliminating up to 1,300 jobs, shifting management roles throughout the business and promoting its financial chief. The medical-devices company announced the news while saying it posted a narrower fourth-quarter ...Read More
Boston Scientific Corp. posted a narrower fourth-quarter loss despite a big settlement payment, but the medical-device maker unveiled steps to shake up management and streamline operations. Boston Scientific said the restructuring will combine its cardiovascular and cardiac-rhythm groups and eliminate its ...Read More
WASHINGTON (AP) - Medical device maker Boston Scientific Corp. spent $480,000 in the fourth quarter to lobby the federal government on the health reform effort as well as other health care-related matters. The Natick, Mass.-based company lobbied on proposals that would ...Read More
NEW YORK -- The following stocks were among those that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market: Boston Scientific Corp. ( BSX - news - people ), down 21 cents at ...Read More
Boston Scientific to pay JNJ $1.73B in settlement WASHINGTON — Boston Scientific said Monday it will pay medical device rival Johnson and Johnson $1.73 billion to settle several seven-year-old patent disputes over drug-coated stents. Boston Scientific will pay Johnson & Johnson's Cordis ...Read More
Stent-makers of the past and future - names like like J&J, Boston Scientific, Guidant and Medtronic - are in the business of making little devices that help prop open arteries post surgery. But sometimes it seems they're in a different ...Read More
CHICAGO (Reuters) - Boston Scientific Corp (BSX.N) said on Monday it will pay $1.73 billion to Johnson and Johnson (JNJ.N) to settle three patent disputes involving heart stents that date back to 2003. The deal comes as medical device maker Boston ...Read More
Boston Scientific Corp. said Monday it would pay Johnson & Johnson a hefty $1.73 billion to end more disputes in long-running legal battles over patents for heart stents. The deal clears away some major legal exposure for Boston Scientific, but it ...Read More
* Boston Scientific settles three patent disputes with J&J * Boston Scientific to pay $1.73 billion to J&J * Sees no significant impact on debt covenants * J&J shares up 0.4 pct (Adds details on financing, patent disputes) NEW YORK, Feb 1 (Reuters) - ...Read More
MINNEAPOLIS - Medtronic, Inc., said Monday it will acquire Invatec, which makes cardiovascular intervention devices, and two affiliated companies for an initial payment of $350 million. The Minneapolis medical technology company says its agreement calls for Medtronic to make additional payments ...Read More
Medical device maker Medtronic Inc. said Thursday that it and its foundation will donate up to $1 million toward earthquake relief and rebuilding in Haiti. The company said its foundation will give $750,000 to help rebuild health care infrastructure in the ...Read More
